GLP-1 / Weight Loss

Ozempic vs Mounjaro: Which GLP-1 Drug Is Right for You?

Verdict Summary

Mounjaro (tirzepatide) produces greater average weight loss in clinical trials due to its dual GIP/GLP-1 mechanism. Ozempic (semaglutide) has a longer safety track record and broader insurance coverage.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionOzempicMounjaro
Drug ClassGLP-1 agonistGIP + GLP-1 dual agonist
Avg. Weight Loss~15% body weight~20-22% body weight
FDA ApprovedDiabetes + ObesityDiabetes + Obesity
DosingOnce weeklyOnce weekly
Cost~$900-$1,000/month~$1,000-$1,100/month

Ozempic Deep Dive

Ozempic (semaglutide) is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin secretion. It has been on the market since 2017 with an extensive safety database across millions of patients.

Mounjaro Deep Dive

Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors, producing superior weight loss outcomes in the SURMOUNT trials. The dual mechanism appears to have additive effects on appetite suppression and metabolic improvement.

How to Choose

Choose Ozempic if…

  • You want the more established safety record
  • Insurance coverage is a priority
  • You have responded well to GLP-1 monotherapy previously

Choose Mounjaro if…

  • Maximum weight loss is your primary goal
  • You have not responded adequately to GLP-1 monotherapy
  • You want the most clinically studied dual agonist

Consider Both If…

Both are appropriate first-line options for obesity treatment; the choice is often driven by insurance coverage and prescriber preference.

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons